1. Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets

3. Introduction/Background

4. RA Is a Heterogeneous Complex Syndrome[a-d]

5. Different RA Combination Treatments Centered on Single DMARD/Glucocorticoid

6. RA Treatment Strategies: More Important Than the Agent Selected?

7. Time to First Remission: Initial Combination vs Initial Monotherapy—DREAM Registry

8. Or, Sometimes, Is the Agent More Important Than the Strategy
Or, Sometimes, Is the Agent More Important Than the Strategy? The RA-BEGIN Trial

9. Fast-Tracking Patients With High-Risk Early RA

10. Some Potential Prognostic Factors in RA

11. Identifying the At-Risk Patients

12. Biomarker Matrices: SWEFOT Results

13. Can Biologics Be Tapered or Discontinued?

14. Initial Combination of Biologic and MTX in Early RA Is Associated With High Levels of DAS28 Remission

15. Early, Intensive Intervention in Newly Diagnosed Patients: Sustained Remission

16. Steroids in RA: CAMERA-II Study

17. Shared Decision-Making and Patient Preferences

18. Shaping Patient Preferences: Using Imaging to Make RA Real

19. Many Cytokines and Growth Factors Converge on the JAK Signaling Pathway[a-c]

20. JAK Inhibitors: Topline Clinical Results[a-c]

21. Guidelines: Broad Range of Pharmacotherapies Available, But No Clear Selection Criteria

22. Safety Concerns With bDMARDs in RA

23. Educational Agenda for Providers of Patient Education: EULAR Recommendations

24. Potential Toxicities and Overtreatment: Steroids, Results From COBRA-light

25. Deleterious Effects of Steroids on Mortality in RA

26. Remote Monitoring of RA Patients With Aggressive Disease

27. Percentage of Patients With Flare Over Time: Results From the BeSt Study

28. Summary and Conclusions

29. Abbreviations

30. Abbreviations (cont)